Subtype
Skin Squamous Cell Carcinoma
CI-CAN-00003959Explore in graph →
89 active trials1 approved drugs3 evidence items
- NCIt
- C4819
- OncoTree
- CSCC
- DOID
- 3151
- UMLS CUI
- C0553723
- MeSH
- D000099314
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003959Explore in graph →
Clinical trials
211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (39)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07144384 | Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma | completed | Early Phase 1 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06014086 | Intratumoral PH-762 for Cutaneous Carcinoma | completed | Phase 1 | 22 | Phio Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2026 |
| clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04389112 | Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions(MITOSKIN) | completed | N/A | 119 | University Hospital, BordeauxOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03574792 | Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy | completed | Phase 2 | 62 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04480645 | CivaDerm(TM) Surface Therapy Pilot Study | completed | Early Phase 1 | 10 | CivaTech OncologyINDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of California, San DiegoOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03889912 | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | completed | Phase 1 | 97 | Regeneron PharmaceuticalsINDUSTRY | 3 | Jan 21, 2026 | clinicaltrials |
| NCT05482880 | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | completed | — | 78 | Maastricht University Medical CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04154943 | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 79 | Regeneron PharmaceuticalsINDUSTRY | 3 | Dec 23, 2025 | clinicaltrials |
| NCT04454489 | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | completed | Phase 2 | 21 | Wake Forest University Health SciencesOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03836105 | CemiplimAb Survivorship Epidemiology(CASE) | completed | — | 287 | Regeneron PharmaceuticalsINDUSTRY | 2 | Oct 15, 2025 | clinicaltrials |
| NCT00954226 | Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer | completed | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04620200 | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery(MATISSE) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 432 | Regeneron PharmaceuticalsINDUSTRY | 8 | May 28, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT03524326 | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04339062 | Cemiplimab in AlloSCT/SOT Recipients With CSCC(CONTRAC) | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06014697 | OCT and Invasion in Cutaneous Skin Lesions | completed | — | 71 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06020612 | Interobserver Variability Desmoplasia | completed | — | 50 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT04710498 | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04160065 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers | completed | Phase 1 | 23 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04925713 | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | completed | Phase 1 | 5 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02964559 | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | completed | Phase 2 | 11 | Emory UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02324608 | Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer | completed | N/A | 15 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05493826 | Real World Study on the Use of Cemiplimab in Adult Patients in UK(REACT-CEMI) | completed | — | 110 | SanofiINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT02218164 | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03353077 | Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) | completed | N/A | 28 | Alpha Tau Medical LTD.INDUSTRY | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02347813 | Preventing Squamous Cell Skin Cancer | completed | Phase 2 | 12 | University of RochesterOTHER | 0 | Jun 23, 2020 | clinicaltrials |
| NCT01198028 | Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma | completed | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT00126555 | Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01017185 | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions | completed | Phase 1 | 28 | Takara Bio Inc.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02672254 | New Strategies Against Cutaneous Squamous Cell Carcinoma | completed | — | 3 | Corporacion Parc TauliOTHER | 0 | Feb 3, 2016 | clinicaltrials |
| NCT00089180 | T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00563290 | Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2015 | clinicaltrials |
| NCT01500954 | Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma | completed | — | 7 | Ruhr University of BochumOTHER | 1 | Oct 16, 2012 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials